GSK/Valeant's Potiga Gets REMS, Needs DEA Classification For Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
The anti-seizure drug should be available by the end of the year following approval June 10.
You may also be interested in...
Sunovion Sees Advantage For Aptiom As Unscheduled Epilepsy Drug
Dainippon subsidiary plans to launch its next-generation version of carbamazepine in the second half of 2014. Lack of classification as a controlled substance means more direct access to prescribers, company says.
Epilepsy NMEs: A View Of The Playing Field
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.
Epilepsy NMEs: A View Of The Playing Field
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.